Your session is about to expire
← Back to Search
Folic Acid Tablet for Ovarian Cancer
Phase 2 & 3
Waitlist Available
Research Sponsored by Rush University Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 2 years
Awards & highlights
Study Summary
This trial is investigating whether giving folic acid supplements to patients with ovarian or breast cancer who are taking the drug olaparib will help delay or avoid deficiency.
Who is the study for?
This trial is for post-menopausal women over 18 with advanced ovarian or breast cancer starting olaparib treatment. They must have normal organ and bone marrow function, no recent blood transfusions, a life expectancy of at least 16 weeks, and be able to swallow pills. Excluded are those with certain other cancers, recent participation in another clinical study, known hypersensitivity to folic acid or olaparib, previous PARP inhibitor treatment including Olaparib, current folic acid deficiency or supplementation.Check my eligibility
What is being tested?
The study tests if taking folic acid tablets can prevent folate deficiency in patients using the drug olaparib for treating advanced ovarian or breast cancer. Folate deficiency can lead to reduced or stopped cancer treatment; this study aims to see if supplements help avoid that.See study design
What are the potential side effects?
Potential side effects from the intervention (folic acid tablet) may include allergic reactions for those sensitive to its components. However, since it's a vitamin supplement being tested alongside olaparib therapy rather than a new medication itself, significant side effects are not commonly expected.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to approximately 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 2 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Frequency of Folate Deficiency
Timing of Folate Deficiency
Secondary outcome measures
Complete Blood Count (CBC)
Number of olaparib discontinuations
Number of olaparib dose interruptions
+5 moreTrial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Folic AcidExperimental Treatment1 Intervention
Folic Acid supplement 1 mg by mouth daily
Group II: No SupplementationActive Control1 Intervention
Find a Location
Who is running the clinical trial?
Rush University Medical CenterLead Sponsor
423 Previous Clinical Trials
164,113 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What are the results of past studies done on the effects of Folic Acid Tablet?
"There are currently 14 Folic Acid Tablet clinical trials ongoing with 2 in Phase 3. Most trials are based in Hangzhou, Zhejiang but there are 36 total locations for these trials."
Answered by AI
For what medical reasons is this pill most often prescribed?
"The recommended course of treatment for those with nutritional deficiencies, folate deficiency, and vitamin deficiencies is Folic Acid Tablet."
Answered by AI
Who else is applying?
What state do they live in?
Wisconsin
How old are they?
18 - 65
What site did they apply to?
Rush University Medical Center
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
Share this study with friends
Copy Link
Messenger